- Home
- ETON vs CANG Comparison
ETON vs CANG Comparison
Compare ETON & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | CANG |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.9M | 408.7M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ETON | CANG |
|---|---|---|
| Price | $16.70 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $29.67 | $3.00 |
| AVG Volume (30 Days) | 216.1K | ★ 926.3K |
| Earning Date | 03-17-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $70,316,000.00 | ★ $621,628,844.00 |
| Revenue This Year | $107.23 | $4,290.41 |
| Revenue Next Year | $29.72 | $8.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 102.77 | ★ 1534.99 |
| 52 Week Low | $11.09 | $0.87 |
| 52 Week High | $23.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | ETON | CANG |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 22.18 |
| Support Level | $14.49 | $0.88 |
| Resistance Level | $15.01 | $1.03 |
| Average True Range (ATR) | 0.64 | 0.10 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 91.53 | 0.89 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CANG Cango Inc. each representing two (2)
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.